MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial

A Alexander T. Pearson J Jameel Muzaffar K Kedar Kirtane E Emily Bellile K Krithika Suresh A Ari J. Rosenberg (Department of Medicine, Section of Hematology and Oncology and Comprehensive Cancer Center, University of Chicago, Chicago) F Francis Worden C Christine H. Chung E Everett Vokes J J. Chad Brenner A Apurva Bhangale J Jon McHugh K Kristy Warner F Felipe Nor J Jacques E. Nor K Keri Innes Y Yifan Zhai T Tommy Fu P Paul L. Swiecicki

Article Details

Volume / Issue Vol. 17, Issue 1
Published March 19, 2026
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (19)

A

Alexander T. Pearson

J

Jameel Muzaffar

K

Kedar Kirtane

E

Emily Bellile

K

Krithika Suresh

A

Ari J. Rosenberg

Department of Medicine, Section of Hematology and Oncology and Comprehensive Cancer Center, University of Chicago, Chicago

F

Francis Worden

C

Christine H. Chung

E

Everett Vokes

J

J. Chad Brenner

A

Apurva Bhangale

J

Jon McHugh

K

Kristy Warner

F

Felipe Nor

J

Jacques E. Nor

K

Keri Innes

Y

Yifan Zhai

T

Tommy Fu

P

Paul L. Swiecicki